Posted on 10 August 2015
Tags: big biotech, big pharma, biotech, partnering, pharma
An interview with Richard Brudnick, Senior VP, Corporate Development, Biogen
De-risking has evolved from literature searches to the cultivation of many wide-ranging relationships throughout the life sciences strata, according to Richard Brudnick, Senior VP, Corporate Development at Biogen. In a recent interview, Brudnick outlined key strategies to accessing innovation and “de-risking” risk through collaboration. Read the full story
Posted on 28 April 2015
Tags: big biotech, big pharma, Celgene, M&A
Celgene and Quanticel Pharmaceuticals announced a definitive share purchase agreement under which Celgene will acquire Quanticel Read the full story
Posted on 20 April 2015
Tags: big biotech, big pharma, partnering
Immunocore will conduct a Phase Ib/II clinical trial combining checkpoint inhibitors MEDI4736 (anti-PD-L1) and/or tremelimumab (anti-CTLA-4) with IMCgp100 Read the full story
Posted on 14 April 2015
Tags: big biotech, Celgene, financing
Mesoblast has entered into an Agreement with Celgene Read the full story
Posted on 27 March 2015
Tags: big biotech, big biotech company, big pharma, partnering, termination
MorphoSys has regained rights to MOR202 from Celgene Read the full story
Posted on 22 January 2015
Tags: big biotech, big pharma, biotech, partnering
Zymeworks announced a collaboration and licensing agreement with Celgene for the research, development, and commercialization of bi-specific antibody therapeutics enabled using Zymeworks’ proprietary Azymetric platform Read the full story
Posted on 23 December 2014
Tags: Amgen, big biotech, big pharma
Amgen and LabCentral biopharma partners: announced an agreement in which Amgen has become a LabCentral platinum sponsor. Read the full story
Posted on 02 December 2014
Tags: big biotech, big pharma, Servier
GeNeuro has entered into a strategic partnership with Servier to develop and market GNbAC1 in Multiple Sclerosis Read the full story
Posted on 02 December 2014
Tags: big biotech, big pharma, Janssen biotech, licensing, partnering
Modern Biosciences has entered into an R&D alliance and global option and licence agreement with Janssen Biotech in relation to MBS’ novel bone-protective compounds for the treatment of rheumatoid arthritis Read the full story
Posted on 26 November 2014
Tags: big biotech, big pharma, biotech, partnering
Transposagen Biopharmaceuticals have entered into a research collaboration and worldwide license agreement with Janssen Biotech to develop allogeneic Chimeric Antigen Receptor T-cells (CAR-T) Read the full story